Because delayed CINV shouldn't define him.
Indication: VARUBI, in combination with other antiemetic agents, is indicated in adults for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
Contraindication: VARUBI is contraindicated in patients with known hypersensitivity to any component of the product (including soybean oil) and in patients taking CYP2D6 substrates with a narrow therapeutic index, such as thioridazine and pimozide. VARUBI can significantly increase the plasma concentrations of thioridazine and pimozide, which may result in QT prolongation and Torsades de Pointes.
CINV, chemotherapy-induced nausea and vomiting
References: 1. VARUBI [package insert]. Waltham, MA: TESARO, Inc.; 2018. 2. Rapoport BL, Chasen MR, Gridelli C, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of cisplatin-based highly emetogenic chemotherapy in patients with cancer: two randomised, active-controlled, double-blind, phase 3 trials. Lancet Oncol. 2015;16(9):1079-1089. 3. Schwartzberg LS, Modiano MR, Rapoport BL, et al. Safety and efficacy of rolapitant for prevention of chemotherapy-induced nausea and vomiting after administration of moderately emetogenic chemotherapy or anthracycline and cyclophosphamide regimens in patients with cancer: a randomised, active-controlled, double-blind, phase 3 trial. Lancet Oncol. 2015;16(9):1071-1078. 4. Wang X, Zhang Z, Arora S, et al. A single-dose bioequivalence study of rolapitant following oral and intravenous administration in healthy subjects. Poster presented at: MASCC/ISOO Annual Meeting of Supportive Care in Cancer; June 23-25, 2016; Adelaide, Australia.